Becker and Duchenne muscular dystrophy are rare, serious, and debilitating muscle disorders. Currently, there are no approved therapies for Becker and while there are treatments available for Duchenne, there remains a high unmet need for additional therapies. Edgewise Therapeutics is investigating a novel approach designed to protect muscle in Becker and Duchenne and the team is excited to share the latest updates with its clinical program in this webinar.

Time: 1:00 pm est.
Duration: 30 minutes